Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trophos Blueprints Path To Exit With Actelion Option Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Trophos' deal with Actelion provides validation for the biotech's approach to rare disease R&D and lines up a solid exit for Trophos' venture backers - if Phase III data lives up to expectations.

You may also be interested in...



Actelion Passes On Trophos Acquisition After Failed Lou Gehrig's Study

Actelion decides not to exercise its option to acquire the Marseille-based French biotech Trophos after the failure of that company's lead compound, olesoxime, in a Phase III study in amyotrophic lateral sclerosis

Actelion Hedge-Fund Shareholder Urges Sale

Hedge fund Elliott Advisors calls for Actelion CEO to quit the board, declaring a sale of the group to be in shareholders' best interests

Actelion Hedge-Fund Shareholder Urges Sale

Hedge fund Elliott Advisors calls for Actelion CEO to quit the board, declaring a sale of the group to be in shareholders' best interests

Related Content

Topics

UsernamePublicRestriction

Register

PS070935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel